Halozyme Therapeutics, Inc. (HALO) Shares Bought by Federated Investors Inc. PA

Federated Investors Inc. PA lifted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 37.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 65,513 shares of the biopharmaceutical company’s stock after purchasing an additional 17,685 shares during the quarter. Federated Investors Inc. PA owned 0.05% of Halozyme Therapeutics worth $840,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ameritas Investment Partners Inc. purchased a new stake in shares of Halozyme Therapeutics in the first quarter worth approximately $122,000. Teacher Retirement System of Texas purchased a new stake in shares of Halozyme Therapeutics in the second quarter worth approximately $129,000. Stifel Financial Corp purchased a new stake in shares of Halozyme Therapeutics in the first quarter worth approximately $187,000. Karp Capital Management Corp purchased a new stake in shares of Halozyme Therapeutics in the first quarter worth approximately $188,000. Finally, IFP Advisors Inc lifted its position in shares of Halozyme Therapeutics by 1.6% in the second quarter. IFP Advisors Inc now owns 14,686 shares of the biopharmaceutical company’s stock worth $188,000 after purchasing an additional 226 shares in the last quarter. 85.06% of the stock is owned by institutional investors and hedge funds.

A number of analysts have recently issued reports on the stock. BMO Capital Markets increased their price target on shares of Halozyme Therapeutics from $14.00 to $15.00 and gave the stock a “market perform” rating in a research report on Friday. Deutsche Bank AG increased their price objective on Halozyme Therapeutics to $20.00 and gave the stock a “buy” rating in a report on Friday. Piper Jaffray Companies increased their price objective on Halozyme Therapeutics from $20.00 to $26.00 and gave the stock an “overweight” rating in a report on Thursday. BidaskClub upgraded Halozyme Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Finally, Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Friday, August 25th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $16.00.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://transcriptdaily.com/2017/09/18/halozyme-therapeutics-inc-halo-shares-bought-by-federated-investors-inc-pa.html.

Halozyme Therapeutics, Inc. (NASDAQ HALO) opened at 16.25 on Monday. Halozyme Therapeutics, Inc. has a one year low of $8.18 and a one year high of $16.65. The firm’s market cap is $2.18 billion. The firm’s 50-day moving average price is $12.79 and its 200 day moving average price is $13.23.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. The company had revenue of $33.80 million for the quarter, compared to the consensus estimate of $31.76 million. During the same quarter in the prior year, the company earned ($0.21) EPS. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post ($0.88) EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply